Institutional Holdings and Trade Data for Novavax, Inc. (NVAX)

In the past 52-week period, shares of Novavax, Inc. (NASDAQ:NVAX) have moved within the range of $0.73 to $1.78. On the stock’s most recent trading day, the company’s shares ended the regular session at $1.14, which is 35.96% higher than its 52-week high.

Novavax, Inc. (NVAX) has demonstrated a 20-day simple moving average (SMA) of 5.21%, and a 50-day SMA of 1.93%. This public company’s current market capitalization stands at $332.40 million.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Checking the amount of enthusiasm that Wall Street analysts hold for a particular stock is crucial when thinking about entering a position. According to the latest data, the consensus recommendation for Novavax, Inc. (NVAX) is Outperform.

Public companies normally post earnings and revenue results that fall somewhat above or below the average Wall Street estimate. In the most recent quarterly financial report, for the quarter ending Jun. 2017, Novavax, Inc. (NVAX) delivered a 6.86% surprise with its net revenue. Sales reached $0.01 billion during the three-month period, compared to the average analyst estimate of $0.01 billion.

Meanwhile, during the same quarter Novavax, Inc. (NVAX) delivered a -1.33% earnings surprise. Net earnings for the quarter were posted at -$0.16 per share, whereas Wall Street had forecast -$0.16 per share.

Ownership at Novavax, Inc. (NVAX), According to Most Recent SEC Filings

A publicly-traded organization’s latest 13F filings tell us important details about its institutional ownership. Novavax, Inc. (NVAX) has 0 billion shares outstanding currently, 39.71% of which belong to institutional investors. Those institutional holdings amount to $0.14 billion.

Additionally, according to the most recent 13F filing from Novavax, Inc. (NVAX), there were 13 new positions totaling 2,665,801 shares of the company’s stock. There were 18 sold out positions, on the other hand, totaling 1,133,945 shares.

Short, Medium and Long Term Indicators

Assessing the average trade volume of a public company’s stock in the short, medium and long term is helpful to gain an understanding of trading activity and investor sentiment. Novavax, Inc. (NVAX) has had a 20-day average volume of 3,715,220 shares, with an average of 40% of short term indicators pointed at Buy.

The stock’s 50-day average volume has been 4,248,622 shares, with an average of 25% of medium term indicators pointing toward Buy. Finally, its 100-day average volume is 5,518,722 shares with 33% of long-term indicators pointing to Buy.